There is a pressing need for effective preventive, diagnostic and therapeutic solutions, implemented at scale, and for patients and their families to have the ability to understand and manage their care.
AD-RIDDLE will offer healthcare providers a suite of validated solutions to match patients with the right interventions at the right time.
Source: Alzheimer Europe
There is a pressing need for effective preventive, diagnostic and therapeutic solutions, implemented at scale, and for patients and their families to have the ability to understand and manage their care.
AD-RIDDLE will offer healthcare providers a suite of validated solutions to match patients with the right interventions at the right time.
AD-RIDDLE’s digital portal will include self-guided assessment tools for EU citizens, pathways for timely referral to healthcare providers, and tailored resources that connect to the next best step.
Providers will have access to a suite of validated digital cognitive assessments and blood-based biomarkers, intended to increase accuracy in risk detection and early diagnosis.
The toolkit for healthcare providers will unite best-in-class research, science, and outcomes data to enable differential diagnosis and inform personalized plans for prevention and care.
Patients will be matched with the right interventions at the right time, including lifestyle interventions and pharmacological treatments.
The AD-RIDDLE platform will allow for flexible adaptation and application in diverse settings, from memory clinics, to primary care, to the broader population outside of healthcare systems.
A real-world testing study will be conducted in these settings across 6 European countries, and will provide extensive evidence to support implementation of diagnostic tools, treatments and lifestyle interventions. To facilitate new findings on Alzheimer’s disease research, data from the AD-RIDDLE study will be hosted in a GDPR-compliant manner on the European Platform for Neurodegenerative Diseases.
